141 related articles for article (PubMed ID: 36725152)
1. Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
Chatterji S; Krzoska E; Thoroughgood CW; Saganty J; Liu P; Elsberger B; Abu-Eid R; Speirs V
Lancet Oncol; 2023 Feb; 24(2):e74-e85. PubMed ID: 36725152
[TBL] [Abstract][Full Text] [Related]
2. "Omics" of HER2-positive breast cancer.
Bravatà V; Cammarata FP; Forte GI; Minafra L
OMICS; 2013 Mar; 17(3):119-29. PubMed ID: 23421906
[TBL] [Abstract][Full Text] [Related]
3. Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
de Ruijter TC; van der Heide F; Smits KM; Aarts MJ; van Engeland M; Heijnen VCG
Breast Cancer Res; 2020 Jan; 22(1):13. PubMed ID: 32005275
[TBL] [Abstract][Full Text] [Related]
4. A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.
Humphries MP; Sundara Rajan S; Droop A; Suleman CAB; Carbone C; Nilsson C; Honarpisheh H; Cserni G; Dent J; Fulford L; Jordan LB; Jones JL; Kanthan R; Litwiniuk M; Di Benedetto A; Mottolese M; Provenzano E; Shousha S; Stephens M; Walker RA; Kulka J; Ellis IO; Jeffery M; Thygesen HH; Cappelletti V; Daidone MG; Hedenfalk IA; Fjällskog ML; Melisi D; Stead LF; Shaaban AM; Speirs V
Clin Cancer Res; 2017 May; 23(10):2575-2583. PubMed ID: 27986751
[No Abstract] [Full Text] [Related]
5. How may targeted proteomics complement genomic data in breast cancer?
Guerin M; Gonçalves A; Toiron Y; Baudelet E; Audebert S; Boyer JB; Borg JP; Camoin L
Expert Rev Proteomics; 2017 Jan; 14(1):43-54. PubMed ID: 27813428
[TBL] [Abstract][Full Text] [Related]
6. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic DDX3 as prognosticator in male breast cancer.
van der Pol CC; Moelans CB; Manson QF; Batenburg MCT; van der Wall E; Borel Rinkes I; Verkooijen L; Raman V; van Diest PJ
Virchows Arch; 2021 Oct; 479(4):647-655. PubMed ID: 33974127
[TBL] [Abstract][Full Text] [Related]
8. Update on prognostic and predictive biomarkers of breast cancer.
Hou Y; Peng Y; Li Z
Semin Diagn Pathol; 2022 Sep; 39(5):322-332. PubMed ID: 35752515
[TBL] [Abstract][Full Text] [Related]
9. The Significance of Proteomic Biomarkers in Male Breast Cancer.
Zografos E; Gazouli M; Tsangaris G; Marinos E
Cancer Genomics Proteomics; 2016; 13(3):183-90. PubMed ID: 27107060
[TBL] [Abstract][Full Text] [Related]
10. Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group.
Geiersbach KB; Chen H; Emmadi R; Haskell GT; Lu X; Liu YJ; Swisshelm K
Cancer Genet; 2020 Jun; 244():11-20. PubMed ID: 32087595
[TBL] [Abstract][Full Text] [Related]
11. The molecular genetic make-up of male breast cancer.
Moelans CB; de Ligt J; van der Groep P; Prins P; Besselink NJM; Hoogstraat M; Ter Hoeve ND; Lacle MM; Kornegoor R; van der Pol CC; de Leng WWJ; Barbé E; van der Vegt B; Martens J; Bult P; Smit VTHBM; Koudijs MJ; Nijman IJ; Voest EE; Selenica P; Weigelt B; Reis-Filho JS; van der Wall E; Cuppen E; van Diest PJ
Endocr Relat Cancer; 2019 Oct; 26(10):779-794. PubMed ID: 31340200
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
13. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
14. Advances in prognostic markers for colorectal cancer
Duan L; Yang W; Wang X; Zhou W; Zhang Y; Liu J; Zhang H; Zhao Q; Hong L; Fan D
Expert Rev Mol Diagn; 2019 Apr; 19(4):313-324. PubMed ID: 30907673
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
16. The biology of male breast cancer.
Fentiman IS
Breast; 2018 Apr; 38():132-135. PubMed ID: 29316513
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.
Ray SK; Mukherjee S
Curr Mol Med; 2022; 22(10):835-850. PubMed ID: 34872474
[TBL] [Abstract][Full Text] [Related]
18. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
19. Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.
Natrajan R; Sailem H; Mardakheh FK; Arias Garcia M; Tape CJ; Dowsett M; Bakal C; Yuan Y
PLoS Med; 2016 Feb; 13(2):e1001961. PubMed ID: 26881778
[TBL] [Abstract][Full Text] [Related]
20. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
